GET DAILY SIGNALSThermo Fisher Scientific (TMO): Charting a Path Toward the +11% Upside at $775
Key Takeaways
- The central target of $775 is the average of verified analyst price targets that sit above the current share price, not a headline consensus figure.
- The overall mean of all valid analyst targets reviewed was about $752, within a wide low-to-high range of roughly $590 to $830.
- At the latest verified close of $698.34, reaching $775 implies an upside of about 11%.
- The strongest support comes from broad-based recovery in life sciences tools demand, consistent earnings beats, and a wave of late-2026 upgrades and target increases.
- The biggest risks are a still-premium valuation, an extended multi-year rally, insider selling, and lingering unevenness in research-and-development spending by biopharma customers.
- For more on Thermo Fisher Scientific (TMO), including its Major News, Today's Price Move, Forecast, and Earnings, explore Tickeron's dedicated pages for additional detail.
- For automated trade ideas across the market, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Thermo Fisher Scientific Inc. (TMO), the Waltham, Massachusetts-based life sciences tools, analytical instruments, and diagnostics giant, carries broad sell-side coverage. Because the overall average of all valid targets landed slightly under 10% above the latest price, the central target here is calculated from the subset of targets above the current share price.
Across the full set of recent targets reviewed, the low-to-high range spanned roughly $590 to $830, with an overall mean near $752. That average, however, implied only about 7–8% upside from the latest close, so it does not meet a meaningful distance test. Averaging the recent targets above the market price yields a figure near $774, rounded to $775. When I reviewed the recent targets, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent individual calls include Barclays at $775, Argus Research at $780, Bank of America at $795, J.P. Morgan at $820, Citi at $800, TD Cowen at $810, Stifel at $775, Baird at $756, Guggenheim at $740, and Morgan Stanley at $730. The spread reflects differing assumptions about how quickly biopharma research-and-development (R&D) spending recovers and how much premium the stock's multiple can sustain. A rare dissent came from DZ Bank, which downgraded the shares to Hold in late October.
Current Market Position and Path Toward the Target
Shares closed at $698.34 on November 3, 2026, near the top of a 52-week range that has seen the stock climb from below $436 to roughly $712. Reaching $775 would require a move of about 11%, which is a modest advance by the standards of this year's rally.
The company has consistently exceeded consensus, most recently reporting adjusted EPS of $6.68 versus roughly $6.40 expected and revenue of $12.14 billion, up about 9% year over year. A continued cadence of earnings beats and guidance raises could support incremental multiple expansion toward the target, though the stock already trades at a forward valuation in the mid-to-high 20s on estimated EPS.
What Could Support a Move Toward the Target
- A broad-based recovery in life sciences tools and instrument demand into 2026, cited repeatedly in recent analyst notes.
- Consistent quarterly outperformance and rising full-year EPS estimates (roughly $25 for 2026, with further growth expected next year).
- A steady stream of upgrades and target increases in late 2026, including Citi, J.P. Morgan, HSBC, KeyBanc, and Goldman Sachs turning more constructive.
- Thermo Fisher's scale and "one-stop-shop" position serving pharma and biotech customers, which analysts view as a competitive moat.
- Portfolio streamlining and divestitures that several firms argue sharpen focus and improve the risk-reward profile.
What Could Prevent the Target From Being Reached
- A premium valuation that leaves limited room for error if growth decelerates.
- Uneven R&D spending by biopharma clients, a key demand driver for the company's tools and consumables.
- Insider selling has picked up over recent months, a sentiment signal some investors watch closely.
- Two years of limited organic revenue growth and a multi-year decline in operating margin, noted in one independent review.
- Sector rotation away from healthcare and life sciences if macroeconomic conditions shift.
Technical Levels and Market Structure
The stock is consolidating just below its 52-week high near $712. A durable resistance zone sits in the $710–$715 area, which the shares would need to clear to open a path toward $750 and then $775. On the downside, support appears near the prior consolidation zone around $670–$680, with the psychologically important $700 level now acting as a pivot. The long-term uptrend remains intact above the $600 area.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms use different model windows and assumptions. Investors should watch the next quarterly earnings report and full-year 2027 guidance, any further analyst revisions or rating changes, and biopharma capital-spending trends. Broader inputs such as interest-rate decisions from the FOMC and healthcare-sector fund flows can also influence the multiple investors are willing to pay. From what I see, monitoring these elements closely helps clarify whether the $775 level remains realistic.
Exploring AI Tools for Research Efficiency
In my own process, Tickeron's AI Daily Buy/Sell Signals has become a useful addition for tracking names like TMO. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on market conditions, technical behavior, and AI-driven analysis. It helps surface opportunities and shifting trends more efficiently than manual reviews alone, which is why I turn to it when evaluating momentum around analyst targets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for TMO turns positive, indicating new upward trend
TMO saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 59 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 192 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 132 of 244 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 17 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 47%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 67 cases where TMO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
The Moving Average Convergence Divergence Histogram (MACD) for TMO turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 22 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 51%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 14 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.901) is normal, around the industry mean (65.986). P/E Ratio (37.525) is within average values for comparable stocks, (3.066). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of analytical and environment monitoring instruments
Industry MedicalSpecialties
Advertisement